The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1559
November 5, 2018
View Complete Issue         Table of Contents 2019 
Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic
November 5, 2018 (Issue: 1559)
The FDA has approved the new aminoglycoside antibiotic plazomicin (Zemdri – Achaogen) for IV treatment of adults with complicated urinary tract infections (cUTIs). Plazomicin is active against multi-drug- resistant Enterobacteriaceae, including...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic
Article code: 1559b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.